Fig 1: Impact of glycyrrhetinic acid on signal proteins in the phosphatidylinositol 3-kinase/protein kinase B signaling pathway. A: Expression levels of insulin receptor and glycogen synthase kinase-3 proteins; B: Protein levels of phosphatidylinositol 3-kinase (PI3K)/p-PI3K and protein kinase B (AKT)/p-AKT. The sequence from left to right represents the control group, the model group, and the glycyrrhetinic acid group. aP < 0.05, bP < 0.01, cP < 0.001. GA: Glycyrrhetinic acid; CON: Control; MOD: Model; GSK3: Glycogen synthase kinase-3; INSR: Insulin receptor; AKT: Protein kinase B; PI3K: Phosphatidylinositol 3-kinase.
Fig 2: MGST1 activated PI3K/AKT/mTOR pathway. Groups were divided into the control, CoCl2, CoCl2 + siNC, CoCl2 + siMGST1, CoCl2 + NC, and CoCl2 + MGST1 group. Western blot analysis assessed the levels of PI3K/AKT/mTOR pathway-associated proteins (AKT, p-AKT, PI3K, P-PI3K, mTOR, and p-mTOR). * P < 0.05, ** P < 0.01, *** P < 0.001.
Fig 3: Myricetin targets the EGFR-AKT/STAT pathway to inhibit neuroinflammation. (A) Venn diagram of TBI targets. (B) Venn diagram of drug-disease intersection targets. (C) Regulatory network of myricetin's interaction with targets. (D) Protein interaction network of key targets. (E) Barplot depicting KEGG pathway enrichment analysis. (F) Molecular docking of myricetin with EGFR and AKT. (G) Representative Western blot results for EGFR, P-STAT1, P-STAT3, P-AKT, and corresponding quantitative analysis. n.s., p > 0.05, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. The results are presented as mean ± standard deviation (n = 3).
Fig 4: Diagram of the effect of glycyrrhetinic acid on the PI3K/AKT signaling pathway. GSK3: Glycogen synthase kinase-3; INSR: Insulin receptor.
Fig 5: NLRX1 regulates the PI3K/AKT signaling pathway in esophageal squamous cell carcinoma. (A) Evaluation of the impact of NLRX1 on the PI3K/AKT pathway in KYSE450 cells measured through WB experiments. (B) Evaluation of the impact of NLRX1 on the PI3K/AKT pathway in ECA109 cells measured through WB experiments. *P<0.05. NLRX1, nucleotide binding and oligomeric domain-like receptor X1; NC, negative control; siNLRX1, small interfering RNA targeting NLRX1; OE, overexpression; P-AKT, phosphorylated AKT; WB, western blot.
Supplier Page from Abcam for PI3K/AKT signalling pathway panel